REG - ValiRx PLC - Result of GM, Issue of Equity, Warrants and TVR
30/12/2024 13:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241230:nRSd6309Ra&default-theme=true
RNS Number : 6309R ValiRx PLC 30 December 2024
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA,
AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET
ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
30 December 2024
VALIRX PLC
("ValiRx" or the "Company")
Result of General Meeting
Issue of Equity, Warrants and Total Voting Rights
Director/PDMR Shareholding
ValiRx plc (the "Company") (AIM: VAL), announces that, further to the
Conditional Fundraising & Notice of General Meeting announcements on 9
December 2024 and 10 December 2024, at its General Meeting held earlier today,
all resolutions were duly passed. Details of the votes received in respect of
the resolutions will be available shortly on the Company's website.
In aggregate the Company has issued 241,999,999 New Ordinary Shares and
241,999,999 Fundraise Warrants over new ordinary shares.
The Fundraise Warrants are exercisable for a period of three years from
Admission and are exercisable at a price of 1.3 pence per new ordinary share.
Director/PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors
and persons closely associated with them who have participated in the
Fundraising are set out in the table below:
Name Number of existing Ordinary Shares Percentage of existing issued share capital Number of New Ordinary Shares Number of Ordinary Shares on Admission Percentage of enlarged share capital on Admission Number of Fundraise Warrants
Mark Eccleston 1,976,957 1.49% 20,769,230(1) 22,746,187 6.08% 20,769,230
Adrian de Courcey 871,036 0.66% 1,538,461 2,409,497 0.64% 1,538,461
Cathy Tralau-Stewart 66,666 0.05% 769,231 835,897 0.22% 769,231
Gerry Desler 195,334 0.15% 769,231 964,565 0.26% 769,231
Martin Gouldstone 0 0.00% 769,231 769,231 0.21% 769,231
Total 3,109,993 2.35% 24,615,384 27,725,377 7.41% 24,615,384
( )
(1)of which, 9,846,145 New Ordinary Shares have been subscribed for by Mark
Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by
OncoLytika Ltd (a company in which Mr. Eccleston is interested) and 2,307,692
New Ordinary Shares have been subscribed for by Mark Eccleston's partner. In
addition, Mr Eccleston subscribed for a further 3,076,923 New Ordinary Shares
as part of the Broker Offer
Issue of Equity
The Placing Shares, the Subscription Shares and the Broker Offer Shares have
been allotted, conditional upon Admission, and application has been made to
the London Stock Exchange for, in aggregate, 241,999,999 Placing Shares,
Subscription Shares and Broker Offer Shares to be admitted to trading on AIM.
Admission is expected to occur at 8.00 a.m. on or around 31 December 2024,
with dealings in the Placing Shares, the Subscription Shares and the Broker
Offer Shares commencing at the same time. The Placing Shares, the Subscription
Shares and the Broker Offer Shares will rank pari passu with all other issued
Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any
shares in the treasury. The above figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in
the Conditional Fundraising announcement dated 9 December 2024, unless
otherwise defined in this announcement.
The Directors of the Company take responsibility for this announcement.
For further information, please contact:
Investor questions on this announcement https://valirx.com/link/vPn48e (https://valirx.com/link/vPn48e)
We encourage all investors to share questions
on this announcement via our investor hub
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com (http://www.valirx.com)
Dr Mark Eccleston, CEO Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880
Liam Murray / Ludovico Lazzaretti
Shard Capital Partners LLP (Sole Broker) Tel: +44 (0) 20 7186 9000
Damon Heath
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz (http://www.vformation.biz)
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name a) Mark Eccleston
b) OncoLytika Ltd
c) Annette Williams
d) Adrian De-Courcey
e) Cathy Tralau-Stewart
f) Gerry Desler
g) Martin Gouldstone
2 Reason for notification
a. Position/Status a) Director
b) A company which Mark Eccleston has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary Shares
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Purchase of shares as part of the Fundraising
c. Price(s) and volume(s)
Price(s) Volume(s)
a) 0.65p a) 12,923,068
b) 0.65p b) 5,538,470
c) 0.65p c) 2,307,692
d) 0.65p d) 1,538,461
e) 0.65p e) 769,231
f) 0.65p f) 769,231
g) 0.65p g) 769,231
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 30/12/2024
f. Place of the transaction Outside a trading venue
2
Reason for notification
a.
Position/Status
a) Director
b) A company which Mark Eccleston has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares
ISIN: GB00BLH13C52
b.
Nature of the transaction
Purchase of shares as part of the Fundraising
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 0.65p
b) 0.65p
c) 0.65p
d) 0.65p
e) 0.65p
f) 0.65p
g) 0.65p
a) 12,923,068
b) 5,538,470
c) 2,307,692
d) 1,538,461
e) 769,231
f) 769,231
g) 769,231
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
30/12/2024
f.
Place of the transaction
Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name a) Mark Eccleston
b) OncoLytika Ltd
c) Annette Williams
d) Adrian De-Courcey
e) Cathy Tralau-Stewart
f) Gerry Desler
g) Martin Gouldstone
2 Reason for notification
a. Position/Status a) Director
b) A company which Mark Eccleston has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Warrants over Ordinary Shares with an exercise price of 1.3 pence per share
and exercisable for a period of three years from Admission.
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Fundraise Warrants received as part of the Fundraising
c. Price(s) and volume(s)
Price(s) Volume(s)
a) 1.3p a) 12,923,068
b) 1.3p b) 5,538,470
c) 1.3p c) 2,307,692
d) 1.3p d) 1,538,461
e) 1.3p e) 769,231
f) 1.3p f) 769,231
g) 1.3p g) 769,231
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction 30/12/2024
f. Place of the transaction Outside a trading venue
2
Reason for notification
a.
Position/Status
a) Director
b) A company which Mark Eccleston has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Warrants over Ordinary Shares with an exercise price of 1.3 pence per share
and exercisable for a period of three years from Admission.
ISIN: GB00BLH13C52
b.
Nature of the transaction
Fundraise Warrants received as part of the Fundraising
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 1.3p
b) 1.3p
c) 1.3p
d) 1.3p
e) 1.3p
f) 1.3p
g) 1.3p
a) 12,923,068
b) 5,538,470
c) 2,307,692
d) 1,538,461
e) 769,231
f) 769,231
g) 769,231
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
30/12/2024
f.
Place of the transaction
Outside a trading venue
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com (http://www.valirx.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMKZMFZZGGGDZMRecent news on ValiRx
See all newsREG - ValiRx PLC - Commercial Update
AnnouncementREG - ValiRx PLC - Termination of Letter of Intent with TheoremRx
AnnouncementREG - ValiRx PLC - Directorate Changes and new Advisory Board
AnnouncementREG - ValiRx PLC - Director Disclosure Update
AnnouncementREG - ValiRx PLC - Conclusion of Evaluation Project
Announcement